





# $\alpha_2$ -Adrenoceptor-mediated vasoconstriction requires a tyrosine kinase

Arti Jinsi, Richard C. Deth \*

Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA
Received 18 July 1994; revised 18 January 1995; accepted 20 January 1995

#### **Abstract**

 $\alpha_2$ -adrenoceptor-mediated contractions of the rabbit saphenous vein were previously found to be inhibited by wortmannin, a protein kinase inhibitor which blocks receptor-dependent phospholipase D activation. Since other studies have indicated that receptor-dependent phospholipase D activation required activity of a tyrosine kinase, we examined the influence of several tyrosine kinase inhibitors on both  $\alpha_2$ -adrenoceptor-mediated contractions of rabbit saphenous vein and  $\alpha_1$ -adrenoceptor-mediated contractions of rabbit aorta. Methyl 2,5-dihydroxycinnamate, genistein and erbstatin each caused non-competitive inhibition of rabbit saphenous vein contractions elicited by the  $\alpha_2$ -adrenoceptor-selective agonist 5-bromo-6-[2-imidazolin-2-yl-amino]-quinoxaline (UK14304), yielding complete inhibition at 100  $\mu$ M and IC<sub>50</sub> values of 15, 35 and 40  $\mu$ M respectively. By contrast, phenylephrine-induced dose-response curves in rabbit aorta were largely unaffected by tyrosine kinase inhibitors at 50  $\mu$ M. In a separate analysis of intracellular Ca<sup>2+</sup>-dependent and extracellular Ca<sup>2+</sup>-dependent  $\alpha_1$ -adrenoceptor responses of rabbit aorta, genistein (50  $\mu$ M) did partially reduce the initial intracellular Ca<sup>2+</sup>-dependent response, but did not reduce maximal response. Methyl 2,5-dihydroxycinnamate (25  $\mu$ M) had no effect on intracellular or extracellular Ca<sup>2+</sup> responses in rabbit aorta. High K<sup>+</sup>-induced contractions of both rabbit saphenous vein and aorta were unaffected by up to 100  $\mu$ M of the tyrosine kinase inhibitors. These results indicate an obligatory requirement for tyrosine kinase activity in  $\alpha_2$ -adrenoceptor-mediated but not  $\alpha_1$ -adrenoceptor-mediated vasoconstriction.

Keywords:  $\alpha_2$ -Adrenoceptor; Tyrosine kinase inhibitor; Phospholipase D

# 1. Introduction

Postjunctional  $\alpha_1$ - and  $\alpha_2$ -adrenoceptors both mediate pressor responses via the contraction of vascular smooth muscle. The varied distribution of these postjunctional adrenoceptors ( $\alpha_1$  and  $\alpha_2$ ) in the vasculature makes them suitable for differentially regulating vascular tone. Larger arterioles and venules are regulated by both  $\alpha_1$ - and  $\alpha_2$ -adrenoceptors while terminal vessels are subserved primarily by  $\alpha_2$ -adrenoceptors (Faber, 1988). The efficacy of  $\alpha_2$ -adrenoceptors to elicit contractility is much lower than that of  $\alpha_1$ -adrenoceptor even in vascular preparations where  $\alpha_2$ -adrenoceptor density is high (Daniel et al., 1991). It has been suggested that efficacy and potency of  $\alpha_2$ -adrenoceptor contractile response can be facilitated by co-

Although  $\alpha_2$ -adrenoceptors have been linked to inhibition of adenylyl cyclase via pertussis toxin-sensitive G-proteins ( $G_i$ ), in many instances there is no causal relationship between the decrease in cAMP levels and the biologic response (Andrade and Aghajanian, 1985;

stimulation with angiotensin II (Dunn et al., 1991a), Bay K 8644, endothelin-1 and KCl (Shimamoto et al., 1992) possibly by augmenting Ca<sup>2+</sup> influx. Similarly Daly et al. (1988) found that co-stimulation of  $\alpha_1$ -adrenoceptors augmented  $\alpha_2$ -adrenoceptor efficacy in rabbit saphenous vein. The  $\alpha_2$ -adrenoceptor contractile response is almost totally dependent on extracellular  $Ca^{2+}$  influx, unlike the  $\alpha_1$ -adrenoceptor response which initially relies on the release of intracellular Ca<sup>2+</sup> from internal stores. However, sensitivity of this Ca<sup>2+</sup> entry during  $\alpha_2$ -adrenoceptor response to voltage-dependent Ca2+ channel blockers has been reported to be variable in different vascular preparations (Dunn et al., 1991b). Dependence on extracellular Ca<sup>2+</sup> entry may reflect a facilitation of receptor coupling rather than direct promotion of myosin phosphorylation (Aburto et al., 1995).

<sup>\*</sup> Corresponding author. Department of Pharmaceutical Sciences, 312 Mugar Hall, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. Tel. (617) 373-4064, fax (617) 266-6756.

Limbird et al., 1985). Recent studies in our laboratory have shown that  $\alpha_2$ -adrenoceptor stimulation in rabbit saphenous vein generates phosphatidic acid and diacylglycerol, possibly through a phospholipase D pathway (Aburto et al., 1995). The cloned  $\alpha_{2A}$ -adrenoceptor expressed in rat 1 fibroblasts has been shown to stimulate phosphatidylcholine hydrolysis via phospholipase D (MacNulty et al., 1992). Further, wortmannin, a kinase inhibitor which interferes with receptor-mediated phospholipase D activity, inhibits  $\alpha_2$ -adrenoceptor-induced contractile response of rabbit saphenous vein in a dose-dependent manner (Waen-Safranchik and Deth, 1994). It therefore seems that phospholipase D may be the downstream effector for  $\alpha_2$ -adrenoceptor in vascular tissues.

Receptor-mediated phospholipase D activation by chemoattractants via the activation of a pertussis toxin-sensitive G-protein has been reported to be associated with tyrosine phosphorylation and tyrosine kinase inhibitors inhibit receptor-induced phospholipase D activity in human neutrophils (Uings et al., 1992). Phospholipase D activity can also be stimulated by receptors with intrinsic tyrosine kinase activity such as the epidermal and platelet-derived growth factor receptor (Ben-Av and Liscovitch, 1989; Fisher et al., 1991) and tyrosine phosphatase inhibitors such as vanadate can facilitate phospholipase D activity in granulocytes by a receptor-independent manner (Bourgoin and Grinstein, 1992). IgE receptor-mediated phospholipase D activation has also been shown to be sensitive to tyrosine kinase inhibitors (Kumada et al., 1993). Thus the present study was designed to investigate the possible involvement of tyrosine kinase activity in  $\alpha_2$ -adrenoceptor-mediated vasoconstrictor response in rabbit saphenous vein as compared to  $\alpha_1$ -adrenoceptor response in rabbit aorta using a series of tyrosine kinase inhibitors. These inhibitors differ structurally from each other and act at either the ATP binding site (genistein) or at the peptide binding site of the tyrosine kinase (erbstatin, methyl 2,5-dihydroxycinnamate). The results of this study suggest that tyrosine kinase activity is necessary for  $\alpha_2$ -adrenoceptor-mediated vasoconstrictor response.

# 2. Materials and methods

# 2.1. Tissue preparation

Male New Zealand rabbits (2–3 kg) were killed by cervical dislocation and the saphenous veins and thoracic aorta were quickly excised and placed in normal Krebs-Henseleit bicarbonate buffer of the following composition (mM): NaCl 118, KCl 4.7, MgSO<sub>4</sub> · 7H<sub>2</sub>O 1.2, CaCl<sub>2</sub> 2.5, NaHCO<sub>3</sub> 25, KH<sub>2</sub>PO<sub>4</sub> 1.2, glucose 11.1, equilibrated with 95% O<sub>2</sub> and 5% CO<sub>2</sub> to final pH of

7.4 (Alabaster et al., 1985). Tissues were cleaned of adhering fat and connective tissue and cut into strips for contraction studies.

## 2.2. Contraction studies

Spiral strips from saphenous vein or transverse strips of aorta were mounted in a 20 ml jacketed water bath maintained at 37° C. One end of the tissue was fixed while the other was connected to a force transducer. Tissues were stretched to a passive tension of 2 g and were allowed to equilibrate for 60 min. After this equilibration period, only when a high concentration (1  $\mu$ M) of the appropriate agonist (i.e. UK14304 for rabbit saphenous vein and phenylephrine for rabbit aorta) showed two successive responses within 10% of each other was the experimental protocol started. Isometric contractions were recorded on a polygraph recorder.

To provide optimal  $\alpha_2$ -adrenoceptor responses in rabbit saphenous vein, experiments were conducted in a buffer with elevated KCl (15 mM) also containing the  $\alpha_1$ -adrenoceptor antagonist prazosin (0.1  $\mu$ M) as described by Shimamoto et al. (1992). This buffer was prepared by replacing an equimolar amount of NaCl with KCl. In order to generate Ca<sup>2+</sup> concentration-response curves in rabbit saphenous vein or aorta the normal Krebs-Henseleit bicarbonate buffer was replaced with Ca2+-free buffer containing 1 mM EGTA for 5 min followed by two washes in Ca2+-free buffer during a further 10 min period before addition of cumulative concentration of CaCl2. Treatment with different tyrosine kinase inhibitors was achieved by incubating the tissues for 30 min before and during the contraction curve. A depolarizing concentration of KCl (60 mM) was used to determine maximal contractile ability of the tissue.

# 2.3. Drugs

UK14304 was provided by Research Biochemicals International as part of the Chemical Synthesis Program of the National Institute of Mental Health, Contract 278-90-007 (Natick, MA, USA). Phenylephrine was purchased from Sigma Chemicals (St. Louis, MO, USA). Tyrosine kinase inhibitors were kindly provided to us by Dr. Alan Hudson of the Wellcome Foundation (Beckenham, Kent, UK). UK14304 and tyrosine kinase inhibitors were dissolved in DMSO whose final bath concentration (0.1%) did not affect tissue contractility.

## 2.4. Statistical analysis

Data means were analyzed for Student's *t*-test. A probability of  $P \le 0.05$  was selected as a criterion for statistical significance.

### 3. Results

We tested the activity of tyrosine kinase inhibitors under conditions of elevated K<sup>+</sup> in the rabbit saphenous vein using the  $\alpha_2$ -adrenoceptor-selective agonist UK14304. Fig. 1 shows the ability of tyrosine kinase inhibitors to inhibit  $\alpha_2$ -adrenoceptor contractile response in a dose-dependent and non-competitive manner. Methyl 2,5-dihydroxycinnamate, a cinnamate derivative, was the most potent inhibitor followed by the bioflavonoid genistein while erbstatin, a formamide, was the least potent. IC<sub>50</sub> values were 15, 35 and 40  $\mu$ M respectively with a complete loss of  $\alpha_2$ -adrenoceptor response at 50 or 100  $\mu$ M.  $\alpha_2$ -Adrenoceptor contractile rssponse of rabbit saphenous vein is thus entirely dependent on tyrosine kinase activity.

 $\alpha_2$ -Adrenoceptor contractile response in rabbit saphenous vein and other blood vessels is highly dependent upon extracellular Ca<sup>2+</sup> (Dunn et al., 1991a; Aburto et al., 1995). In order to test the relationship between tyrosine kinase activity and Ca2+ influx, we obtained UK14304 (1  $\mu$ M) response in Ca<sup>2+</sup>-free buffer.  $\alpha_2$ -Adrenoceptor response was completely inhibited under these conditions, while subsequent incremental addition of Ca2+ upto 10 mM increased tone to a level similar to the maximal UK14304 response in normal buffer (Fig. 2). This response, referred to as the extracellular Ca2+-dependent response, was inhibited by methyl 2,5-dihydroxycinnamate (25  $\mu$ M) and genistein (50  $\mu$ M) by 30% and 50%, respectively (Fig. 2A,B). Thus elevation of [Ca<sup>2+</sup>] to 4-fold above normal was only able to partially overcome the effects of tyrosine kinase inhibition.


We also evaluated if these tyrosine kinase inhibitors affect  $\alpha_1$ -adrenoceptor responses in rabbit aorta using the  $\alpha_1$ -adrenoceptor-selective agonist phenylephrine in a dose-response protocol. All three tyrosine kinase inhibitors tested were ineffective in blocking  $\alpha_1$ -adrenoceptor response even at concentrations higher than their IC<sub>50</sub> values in rabbit saphenous vein (data not shown). Thus  $\alpha_1$ -adrenoceptor contractile response is much less sensitive to tyrosine kinase inhibitors than is  $\alpha_2$ -adrenoceptor response.

In studies similar to those for  $\alpha_2$ -adrenoceptors we investigated if these tyrosine kinase inhibitors could separately influence either the initial intracellular Ca<sup>2+</sup> release phase or the slow extracellular Ca2+ entry-dependent phase in rabbit aorta. Genistein (50 µM) inhibited the initial phase by about 55% but did not reduce the influx-dependent phase while methyl 2,5-dihydroxycinnamate (25  $\mu$ M) was essentially without effect on either phase (Fig. 3). This difference may be due to different mechanisms of inhibition by these two structurally distinct tyrosine kinase inhibitors.

In order to rule out inhibition by these tyrosine kinase inhibitors at the level of contractile elements, we tested their effects on contractile response induced by 60 mM KCl (data not shown). High K+-induced contractions of both rabbit saphenous vein and aorta were unaffected by up to 100 μM of tyrosine kinase inhibitors. This indicates the ability of tyrosine kinase inhibitors to selectively interfere with receptor-mediated vasoconstrictor responses, especially the mechanism activated by  $\alpha_2$ -adrenoceptors.

# 4. Discussion

Kinase-dependent protein phosphorylation is an important step in activation of excitation-contraction coupling in vascular smooth muscle cells at the level of contractile elements. Among these groups of kinases,







Fig. 1. Dose-dependent non-competitive effect of tyrosine kinase inhibitors on UK14304 responses in rabbit saphenous vein. Tissues were exposed to different concentrations of methyl 2,5-dihydroxycinnamate, genistein, erbstatin for 30 min prior to eliciting the dose-response curve. Responses have been expressed as a percentage of the maximum response to UK14304 and each data point shown is the mean  $\pm$  S.E.M. of at least four or more determinations.

-6







Fig. 2. Effect of methyl 2,5-dihydoxycinnamate (DHC;A) and genistein (B)  ${\rm Ca^2}^+$ -free and  ${\rm Ca^2}^+$ -dependent responses to the  $\alpha_2$ -adrenoceptor agonist UK14304 in rabbit saphenous vein. Tissues were exposed to tyrosine kinase inhibitors for 30 min prior to eliciting the dose-response curve. Responses have been expressed as a percentage of the maximum response to UK14304 and each data point shown is the mean  $\pm$  S.E.M. of at least four or more determinations. \* Statistical significance at  $P \le 0.05$  from untreated tissues.

protein tyrosine kinases are one of the most abundant in the cell and includes not only receptor tyrosine kinases but also cytosolic tyrosine kinases. The low levels of in vivo tyrosine phosphorylation, when compared with the rapid and pleiotropic cellular responses observed, argues that the cellular targets of protein tyrosine kinases are likely to be amplifiers (Cantley et al., 1991; Pan et al., 1992). The exact nature and physiological significance of tyrosine kinase activity in vascular smooth muscle cells has yet to be identified. Historically, tyrosine kinase activity has been associated with cell growth, proliferation and transformation. More recently, the observation that receptors which stimulate growth encompass not only the classical insulin-like receptors with intrinsic tyrosine kinase activ-

ity but also G-protein-coupled receptors, such as the endothelin-1 receptor, suggests the possible involvement of cytosolic tyrosine kinases such as pp60<sup>c-src</sup> as the common link between the two types of growth factor receptors (Hadcock et al., 1992; Simonson and Herman, 1993).

We sought to investigate the importance of tyrosine kinase activity in the contractile response of two vascular preparations, each containing mainly one  $\alpha$ -adrenoceptor subtype. Rabbit saphenous vein was used as a model for  $\alpha_2$ -adrenoceptor and rabbit aorta for  $\alpha_1$ -adrenoceptor responses. A series of structurally distinct tyrosine kinase inhibitors were examined for their effects on vasoconstriction responses induced by  $\alpha_2$ - or  $\alpha_1$ -adrenoceptor agonist. Our results indicate a critical role for tyrosine kinase activity in  $\alpha_2$ -adrenoceptor but not in  $\alpha_1$ -adrenoceptor responses.






Fig. 3. Effect of methyl 2,5-dihydoxycinnamate (DHC;A) and genistein (B)  $\mathrm{Ca^{2+}}$ -free and  $\mathrm{Ca^{2+}}$ -dependent responses to the  $\alpha_2$ -adrenoceptor agonist UK14304 in rabbit aorta. Tissues were exposed to tyrosine kinase inhibitors for 30 min prior to eliciting the dose-response curve. Responses have been expressed as a percentage of the maximum response to UK14304 and each data point shown is the mean  $\pm$  S.E.M. of at least four of more determinations. \* Statistical significance at  $P \leq 0.05$  from untreated tissues.

Genistein is an isoflavone compound isolated from fermentation broth of *Pseudomonas* sp. and is a highly specific inhibitor of tyrosine kinases. Its inhibition is competitive with respect to ATP and non-competitive for the phosphate acceptor (i.e. protein substrate) such as histone H2B (Akiyama et al., 1987). Genistein inhibits EGF-receptor kinase activity with an IC<sub>50</sub> value of 22  $\mu$ M (Akiyama et al., 1987) and inhibited  $\alpha_2$ -adrenoceptor contractile response in rabbit saphenous vein with an IC<sub>50</sub> value of approximately 35  $\mu$ M. Methyl 2,5-dihydroxycinnamate and erbstatin belong to another class of tyrosine inhibitors which bind to peptide recognition sites and inhibit tyrosine phosphorylation (Powis, 1991). Methyl 2,5-dihydroxycinnamate and erbstatin inhibit EGF receptor-kinase activity with IC50 values of 0.77 and 3.3  $\mu$ M, respectively (Isshiki, 1987; Umezawa et al., 1990) while their IC<sub>50</sub> for inhibition of  $\alpha_2$ -adrenoceptor-mediated contraction of rabbit saphenous vein were 15 and 40  $\mu$ M, respectively. The lower potency might reflect involvement of a different tyrosine kinase; however, the relationship between contraction and kinase activity may not be direct so that IC<sub>50</sub> values for each would not be expected to be the same.

Although the observed rank order potency for inhibition in the rabbit saphenous vein was different than that for inhibition of growth factor receptor tyrosine kinase activity, these tyrosine kinase inhibitors were clearly effective in inhibiting vasoconstrictor response to an  $\alpha_2$ -adrenoceptor agonist in rabbit saphenous vein, providing complete inhibition at  $50-100 \mu M$ . This indicates the obligatory involvement of a non-receptor tyrosine kinase in  $\alpha_2$ -adrenoceptor-mediated vasoconstrictor response. Similar inhibition of agonistinduced contractions by tyrosine kinase inhibitors have also been demonstrated by Di Salvo et al. (1993) in vascular and visceral smooth muscle, however the subtype of the  $\alpha$ -adrenoceptor involved was not identified. In the same study tyrosine kinase inhibitors caused inhibition of pp60<sup>c-src</sup> tyrosine kinase activity while myosin light chain kinase and cAMP-dependent protein kinase activity was unaffected.

Recently numerous reports suggest that chemo-attractant receptor,  $\alpha_2$ -adrenoceptor and angiotensin II receptor are coupled through pertussis toxin sensitive G-proteins to phospholipase D activity (Lasseque et al., 1991; Kessels et al., 1991; MacNulty et al. 1992). Receptor-mediated phospholipase D activity has been shown to be dependent upon tyrosine kinase activity such that tyrosine kinase inhibitors block phospholipase D activation (Thompson et al., 1991; Uings et al., 1992). Our previous findings indicate involvement of a phospholipase D pathway in vascular  $\alpha_2$ -adrenoceptor signal transduction which is wortmannin-sensitive (Aburto et al., 1995; Waen-Safranchik and Deth, 1994). We suggest that tyrosine activity might be essential for  $\alpha_2$ -adrenoceptor-mediated phospholipase D ac-

tivity. Inhibition of this requisite tyrosine kinase activity (such as that provided by pp60<sup>c-src</sup> for example) can thus completely eliminate the  $\alpha_2$ -adrenoceptor-vaso-constrictor response.

Although the exact relationship between a tyrosine kinase and phospholipase D activation remains to be established, we view the role of a tyrosine kinase to be permissive in this pathway. A specific association between the alpha subunit of G<sub>i</sub> and protein tyrosine kinase pp60<sup>c-src</sup> has been reported by Torti et al., 1992). In fact, Jiang et al. (1994) suggest that v-src-induced phospholipase D activity is mediated via cholera and pertussis toxin-insensitive G-proteins. Since src-like tyrosine kinases regulate the activity of monomeric G-proteins, it is therefore possible that  $\alpha_2$ -adrenoceptor-mediated phospholipase D activity can be regulated by the combined obligatory effect of a tyrosine kinase both at the level of heterotrimeric and monomeric G-proteins (Bowman et al., 1993; Cockcroft et al., 1994). While this is a hypothetical mechanism, it serves to illustrate a potential link between tyrosine kinase activity and  $\alpha_2$ -adrenoceptor-induced phospholipase D stimulation.

In rabbit aorta, genistein caused partial inhibition of initial Ca<sup>2+</sup> release-dependent tension whereas methyl 2,5-dihydroxycinnamate was without effect (Fig. 3A,B). Total response was, however, completely recovered after genistein. Genistein is known to act at both the ATP and substrate binding site, unlike methyl 2,5-dihydroxycinnamate which inhibits only the substrate binding site (Akiyama et al., 1989). Thus genistein may exhibit a broader range of inhibition than methyl 2,5dihydroxycinnamate, perhaps extending to some Ca<sup>2+</sup>related process in the rabbit aorta. Since tyrosine kinase activity (Vostal et al., 1991) and low molecular weight G-proteins (Bird and Putney, 1993; Fasolato et al., 1993) have been implicated in the process of refilling releasable Ca2+ stores, genistein inhibition may possibly reflect an impairment of such refilling.

Tyrosine kinase inhibitors did not inhibit excitation-contraction coupling non-specifically since it had no effect on high K<sup>+</sup>-buffer-induced contraction induced in either rabbit saphenous vein or aorta. In these rabbit blood vessels tyrosine kinase activity seems therefore to be of paramount importance in  $\alpha_2$ -adrenoceptor-mediated response and less so in  $\alpha_1$ -adrenoceptor vasoconstrictor response, but not at all involved at the level of contractile elements.

In conclusion, the present study demonstrates for the first time the critical and selective role of tyrosine kinase activity in  $\alpha_2$ -adrenoceptor-mediated vasoconstrictor response. Tyrosine kinase activity may be essential for coupling of  $\alpha_2$ -adrenoceptors to phospholipase D activation, although this mechanism requires additional verification.

### References

- Aburto, T., A. Jinsi, Q.-B. Zhu and R.C. Deth, 1995, Involvement of protein kinase C activation in  $\alpha_2$ -adrenoceptor-mediated contractions of rabbit saphenous vein, Eur. J. Pharmacol. 277, 35.
- Akiyama, T., J. Ishida, S. Nakagawa, H. Ogawara, S.-I. Watanabe, N. Itoh, M. Shibuya, M. and Y. Fukam, 1987, Genistein, a specific inhibitor of tyrosine-specific protein kinases, J. Biol. Chem. 262 (1), 5592.
- Andrade, R. and G.K. Aghajanian, 1985, Opiate and  $\alpha_2$ -adrenoceptor-induced hyperpolarization of locus ceruleus in brain slices: reversal by cyclic adenosine 3',5'-monophosphate analogues, J. Neurosci. 5, 2359.
- Alabaster, A.V., R.F. Keir and C.J. Peters, 1985, Comparison of activity of alpha-adrenergic agonists and antagonists in dog and rabbit saphenous vein, Naunyn-Schmied. Arch. Pharmacol. 330, 33.
- Ben-Av, P. and M. Liscovitch, 1989, Phospholipase D activation by the mitogen platelet-derived growth factor and 12-O-tetradecanoylphorbol 13-acetate in NIH-3T3 cells, FEBS Lett. 259, 64.
- Bird, G.J.St. and J.W. Putney, Jr., 1993, Inhibition of thapsigargin-induced calcium entry by microinjected guanine nucleotide analogues, J. Biol. Chem. 268 (29), 21486.
- Bourgoin, S. and S. Grinstein, 1992, Peroxides of vanadate induce activation of phospholipase D in HL-60 cells, J. Biol. Chem. 267 (17), 11908.
- Bowman, E.P., D.J. Uhlinger and J.D. Lambeth, 1993, Neutrophil phospholipase D is activated by a membrane-associated Rho family small molecular weight GTP-binding protein, J. Biol. Chem. 268 (29), 21509.
- Cantley, L.C., K.R. Auger, C. Carpenter, B. Duckworth, A. Graziani, R. Kapeller and S. Soltoff, 1991, Oncogenes and signal transduction, Cell 64, 281.
- Cockcroft, S., G.M.H. Thomas, A. Fensome, B. Geny, E. Cunningham, I. Gout, I. Hiles, I., N.F. Totty, O. Troung and J.J. Hsuan, 1994, Phospholipase D: A downstream effector of ARF in granulocytes, Science 263, 523.
- Daniel, E.E., A.G. Shi, Z.L. Wang, Y.Y. Guan, K. Hoo, E.J. Cragoe, Jr. and C.Y. Kwan, 1991, Alpha-adrenoceptors in vascular smooth muscle: all is not well, Blood Vessels 28, 104.
- Daly, C.J., J.C. McGrath and V.G. Wilson, 1988, Pharmacological analysis of postjunctional  $\alpha$ -adrenoceptors mediating contractions to (-) noradrenaline in the rabbit isolated lateral saphenous vein can be explained by interacting responses to simultaneous activation of  $\alpha_1$  and  $\alpha_2$ -adrenoceptors, Br. J. Pharmacol. 95, 485.
- Di Salvo, J., A. Steusloff, L. Semenchuk, S. Satoh, K. Kolquist and G. Pfitzer, 1993, Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle, Biochem. Biophys. Res. Commun. 190 (3), 968.
- Dunn, W.R., C.J. Daly, J.C. McGrath and W.G. Wilson, 1991a, A comparison of the effects of angiotensin II and Bay K 8644 on response to moradrenaline mediated via postjunctional  $\alpha_1$  and  $\alpha_2$ -adrenoceptors in rabbit isolated blood vessels, Br. J. Pharmacol. 193, 1475.
- Dunn, W.R., C.J. Daly, J.C. McGrath and W.G. Wilson, 1991b, The effect of nifedipine on  $\alpha_2$ -adrenoceptor-mediated contractions in several isolated blood vessels from rabbit, Br. J. Pharmacol. 103, 1493
- Faber, J.E., 1988, In situ analysis of  $\alpha$ -adrenoceptors on arteriolar and venular smooth muscle in rat skeletal muscle microcirculation, Circ. Res. 62, 37.
- Fasolato, C., M. Hoth and R. Penner, 1993, A GTP-dependent step in the activation mechanism of capacitative calcium influx, J. Biol. Chem. 268 (28), 20737.

- Fisher, G.J., P.A. Henderson, J.J. Voorhees and J.J. Baldassare, 1991, Epidermal growth factor-induced hydrolysis by phospholipase D and phospholipase C in human dermal fibroblasts, J. Cell. Physiol. 146, 309.
- Hadcock, J.R., J.D. Port, M.S. Gelman and C.C. Malbon, 1992, Cross-talk between tyrosine kinase and G-protein-linked receptors, J. Biol. Chem. 267 (36), 26017.
- Isshiki, K., 1987, Inhibition of tyrosine protein kinase by synthetic erbstatin analogs, J. Antibiot. 40 (8), 1209.
- Jiang, H., K. Alexandropoulos, J. Song and D.A. Foster, 1994, Evidence that v-Src-induced phospholipase D activity is mediated by a G-protein, Mol. Cell Biol. 14, 36.
- Kessels, G.C., D. Roos and A.J. Verhoeven, 1991, fMet-Leu-Phe-induced activation of phospholipase D in human neutrophils, J. Biol. Chem. 266 (34), 23152.
- Kumada, T., H. Miyata and Y. Nozawa, 1993, Involvement of tyrosine phosphorylation in IgE receptor-mediated phospholipase D activation in rat basophilic leukemia (RBL-2H3) cells, Biochem. Biophys. Res. Commun. 191 (3), 1363.
- Lasseque, B., R.W. Alexander, M. Clark and K.K.I. Griendling, 1991, Angiotensin II-induced phosphatidylcholine hydrolysis in cultured vascular smooth muscle cells, Biochem. J. 276, 19.
- Limbird, L.E., T.M. Connolly, J.D. Sweatt and H.P. Uderman, 1985, Human platelets alpha-2 adrenergic receptor: effect of Na<sup>+</sup> on interaction with adenylate cyclase system and on epinephrinestimulated platelet secretion, Adv. Cycl. Nucl. Protein Phosphoryl. Res. 19, 235.
- MacNulty, E.E., S.J. McClue, I.C. Carr, T. Jess and M.J.O. Wakelam, 1992,  $\alpha_2$ -C10 phospholipase D-mediated hydrolysis of phosphatidylcholine by interacting with pertussis toxin-sensitive guanine nucleotide-binding proteins, J. Biol. Chem. 265 (22), 10320.
- Pan, M.G., T. Florio and P.J.S. Stork, 1992, G-protein activation of a hormone-stimulated phosphatase in human tumor cells, Science 256, 1215.
- Powis, G., 1991, Signalling targets for anticancer drug development, Trends Pharmacol. Sci. 12, 188.
- Shimamoto, H., J-P. Bourreau, C.Y. Kwan and E.E. Daniel, 1992, Amplification of alpha adrenergic vasoconstriction in canine isolated mesenteric artery and vein, J. Pharmacol. Exp. Ther. 260 (3), 1119.
- Simonson, M.S. and W.H. Herman, 1993, Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1, J. Biol. Chem. 268 (13), 9347.
- Thompson, N.T., R.W. Bonser and L.G. Garland, 1991, Receptorcoupled phospholipase D and its inhibition, Trends Pharmacol. Sci. 12, 404.
- Torti, M., M.F. Crouch and E.G. Lapetina, 1992, Epinephrine induces association of pp60<sup>c-src</sup> with  $G_{i\alpha}$  in human platelets, Biochem. Biophys. Res. Commun. 186 (1), 440.
- Uings, I.J., N.T. Thompson, R.W. Randall, G.D. Spacey, R.W. Bonser, A.T. Hudson and L.W. Garland, 1992, Tyrosine phosphorylation is involved in receptor coupling to phospholipase D but not phospholipase C in human neutrophil, Biochem. J. 281, 597.
- Umezawa, K.K., T. Horti, H. Tajima, M. Imoto, K. Isshiki and T. Takeuchi, 1990, Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors, FEBS Lett. 260, 198.
- Vostal, J.G., W.L. Jackson and N.R. Shulman, 1991, Cytosolic and stored calcium antagonistically control tyrosine phosphorylation of specific platelet proteins, J. Biol. Chem. 266 (25), 16911.
- Waen-Safranchik, V.I. and R.C. Deth, 1994, Effects of wortmannin on alpha-1 and alpha-2 adrenergic receptor-mediated contractile responses in rabbit vascular tissues, Pharmacol. 48, 349.